{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T10:29:31Z","timestamp":1793615371085,"version":"4.5.0"},"reference-count":29,"publisher":"Wiley","issue":"23","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004809","name":"Financiadora de Estudos e Projetos","doi-asserted-by":"publisher","award":["01.25.0191.00"],"award-info":[{"award-number":["01.25.0191.00"]}],"id":[{"id":"10.13039\/501100004809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Rapid Comm Mass Spectrometry"],"published-print":{"date-parts":[[2026,12,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Retatrutide (LY3437943) is a novel long\u2010acting triple incretin receptor agonist that targets the glucagon\u2010like peptide\u20101 receptor (GLP\u20101R), glucose\u2010dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). Its pronounced effects on body composition and metabolic health, combined with increasing off\u2010label use among physically active populations, raise concerns about potential misuse in sport. Despite growing clinical interest and anecdotal reports about use among amateur athletes, information on the detection and elimination profile of retatrutide in humans remains unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A method based on liquid chromatography\u2013high\u2010resolution mass spectrometry (LC\u2010HRMS) dedicated to monitor retatrutide was developed and validated in human plasma and urine in accordance with World Anti\u2010Doping Agency (WADA) criteria. Detection was based on the [M\u2009+\u20093H]\n                      <jats:sup>3+<\/jats:sup>\n                      precursor ion by targeted selected\u2010ion monitoring (t\u2010SIM), with confirmatory analysis via parallel reaction monitoring (PRM) of structurally diagnostic fragment ions. From four retatrutide users who self\u2010administered 2\u2009mg subcutaneously on Days 1 and 7, blood and urine samples were collected at predefined time points following self\u2010administration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The method was proved fit\u2010for\u2010purpose regarding selectivity, reliability, robustness, and stability. Limits of detection (LOD) were evaluated using both empirical \u2265\u200995% detection rate criteria and sigmoidal logistic regression modeling, yielding 6.14\u2009ng\/mL in plasma and 2.44\u2009ng\/mL in urine. Neither intact retatrutide nor metabolite\u2010derived signals were detected in urine samples throughout the entire collection period, despite systematic application of multiple extraction strategies. Plasma concentration\u2013time profiles exhibited nonmonotonic behavior, consistent with prolonged subcutaneous absorption and depot\u2010like release kinetics following repeated dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that plasma represents the appropriate matrix for intact retatrutide detection compared with urine. The extended plasma detection window, approximately 56\u2009days after the first dose, supports plasma\u2010based testing as a suitable analytical strategy for this and related long\u2010acting therapeutic peptides in antidoping testing context.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/rcm.70179","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:02:26Z","timestamp":1789534946000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC\u2010HRMS: Implications for Antidoping Analysis"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1299-4121","authenticated-orcid":false,"given":"Gabriel Reis Alves","family":"Carneiro","sequence":"first","affiliation":[{"name":"LBCD, LADETEC, Instituto de Qu\u00edmica Universidade Federal Do Rio de Janeiro  Rio de Janeiro Brazil"},{"name":"LABPROT, LADETEC, Instituto de Qu\u00edmica Universidade Federal Do Rio de Janeiro  Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle Karine","family":"da Costa Nunes","sequence":"additional","affiliation":[{"name":"LBCD, LADETEC, Instituto de Qu\u00edmica Universidade Federal Do Rio de Janeiro  Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-7255","authenticated-orcid":false,"given":"Gustavo Ramalho","family":"dos Santos Cardoso","sequence":"additional","affiliation":[{"name":"LBCD, LADETEC, Instituto de Qu\u00edmica Universidade Federal Do Rio de Janeiro  Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Fa\u00e7anha","family":"dos Santos","sequence":"additional","affiliation":[{"name":"LBCD, LADETEC, Instituto de Qu\u00edmica Universidade Federal Do Rio de Janeiro  Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-8231","authenticated-orcid":false,"given":"Monica Costa","family":"Padilha","sequence":"additional","affiliation":[{"name":"LBCD, LADETEC, Instituto de Qu\u00edmica Universidade Federal Do Rio de Janeiro  Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5507-7142","authenticated-orcid":false,"given":"F\u00e1bio C\u00e9sar Sousa","family":"Nogueira","sequence":"additional","affiliation":[{"name":"LABPROT, LADETEC, Instituto de Qu\u00edmica Universidade Federal Do Rio de Janeiro  Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8597-416X","authenticated-orcid":false,"given":"Henrique Marcelo Gualberto","family":"Pereira","sequence":"additional","affiliation":[{"name":"LBCD, LADETEC, Instituto de Qu\u00edmica Universidade Federal Do Rio de Janeiro  Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3761"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.07.013"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M205854200"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00726"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(23)01053\u2010X"},{"key":"e_1_2_11_9_1","unstructured":"World Anti\u2010Doping Agency \u201cThe 2024 Prohibited List: International Standard \u201d Wada (2024) https:\/\/www.wada\u2010ama.org\/en\/prohibited\u2010list."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3408"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/aja.2011.178"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2019.09.010"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3835"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2011.03.003"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1710"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.09.009"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(18)32260\u20108"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(22)02033\u20105"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010025\u201096361\u20104"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.5c03725"},{"key":"e_1_2_11_21_1","unstructured":"Waters Corporation \u201cSPE\u2010LC\/MS Bioanalytical Quantification of the Biotherapeutic Peptide Semaglutide From Plasma \u201d Application Note 720008097EN Waters (2023) https:\/\/www.waters.com\/nextgen\/us\/en\/library\/application\u2010notes\/2023\/spe\u2010lc\u2010ms\u2010bioanalytical\u2010quantification\u2010of\u2010the\u2010biotherapeutic\u2010peptide\u2010semaglutide\u2010from\u2010plasma.html."},{"key":"e_1_2_11_22_1","unstructured":"World Anti\u2010Doping Agency \u201cWorld Anti\u2010Doping Code\u2014International Standard for Laboratories (ISL) \u201d Wada (2021) https:\/\/www.wada\u2010ama.org."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3367"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac020361s"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106895"},{"key":"e_1_2_11_26_1","volume-title":"Lilly's Triple Agonist, Retatrutide, Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial","author":"Eli Lilly and Company","year":"2026"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.03.049"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.03.020"},{"key":"e_1_2_11_30_1","unstructured":"World Anti\u2010Doping Agency \u201cWADA Technical Document TD2023IDCR: Minimum Criteria for Chromatographic\u2010Mass Spectrometric Confirmation of the Identity of Analytes for Doping Control Purposes \u201d Wada (2023) https:\/\/www.wada\u2010ama.org."}],"container-title":["Rapid Communications in Mass Spectrometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rcm.70179","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rcm.70179","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rcm.70179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:51:59Z","timestamp":1793613119000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/rcm.70179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":29,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2026,12,15]]}},"alternative-id":["10.1002\/rcm.70179"],"URL":"https:\/\/doi.org\/10.1002\/rcm.70179","archive":["Portico"],"relation":{},"ISSN":["0951-4198","1097-0231"],"issn-type":[{"value":"0951-4198","type":"print"},{"value":"1097-0231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"2026-07-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70179"}}